Abstract
We describe the first cefixime-resistant Neisseria gonorrhoeae strain in Austria that caused treatment failure.It follows the first five cases in Europe of cefixime treatment failure, reported in Norway in 2010 and the United Kingdom in 2011. Effective treatment of gonorrhoea is crucial for public health control and, at present, requires substantially enhanced awareness, more frequent test-of-cure, interaction with experts after therapeutic failure, tracing and therapy of contacts, and surveillance of gonococcal antimicrobial resistance and treatment failures worldwide.
Highlights
We describe the first cefixime-resistant Neisseria gonorrhoeae strain in Austria that caused treatment failure
We report here the first N. gonorrhoeae strain with resistance to cefixime in Austria, which caused a treatment failure with the internationally recommended first-line treatment cefixime
The present treatment failure was identified in an Austrian patient, the infection was contracted in Germany, which suggests that this strain may be present in the MSM community in Germany
Summary
First Neisseria gonorrhoeae strain with resistance to cefixime causing gonorrhoea treatment failure in Austria, 2011. We describe the first cefixime-resistant Neisseria gonorrhoeae strain in Austria that caused treatment failure. It follows the first five cases in Europe of cefixime treatment failure, reported in Norway in 2010 and the United Kingdom in 2011. Effective treatment of gonorrhoea is crucial for public health control and, at present, requires substantially enhanced awareness, more frequent test-of-cure, interaction with experts after therapeutic failure, tracing and therapy of contacts, and surveillance of gonococcal antimicrobial resistance and treatment failures worldwide. We report here the first Neisseria gonorrhoeae strain with resistance to cefixime in Austria, which caused a treatment failure with cefixime. It is possible that gonorrhoea will become untreatable in certain circumstances and especially some settings [1,7]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
